fda and bpc 157 Exciting news for peptides coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- to the 503A Bulks List for use in compounding for 7 peptides under FDA review:

Format Lyophilized Peptide Purity High-Purity Tested Vial sizes Available in Multiple Strengths Storage Refrigerated Storage Recommended Reconstitution Bacteriostatic Water Compatible COA Certificate of Analysis Available Research Domains BPC-157 Supports Tissue Repair

Autoimmune-Mediated Pain: Conditions like rheumatoid arthritis where immune dysregulation drives inflammation and tissue damage may respond to immune-modulating peptides like Thymosin Alpha-1 and KPV

Performing cardiovascular exercise 30-90 minutes after administration ensures mobilized fatty acids are utilized for energy rather than being re-stored

The FDA says that they would not take action against a compounder for using a Category 1 substance but would consider taking action for those that use Category 2 or 3 substances